Dexamethasone intraocular suspension shows strong anti-inflammatory effects

Real-world data on dexamethasone intraocular suspension 9% (DEXYCU, EyePoint Pharmaceuticals) show strong anti-inflammatory efficacy with and without additional topical anti-inflammatory treatment.

The researchers examined the effect of adjunctive topical anti-inflammatory medications on clinical outcomes with sustained-release dexamethasone intraocular suspension 9%. Data were collected from records of patients who received dexamethasone intraocular suspension 9% after cataract surgery between March 12 and December 15, 2019 at multiple sites. Descriptive analysis was undertaken to examine the effect of adjectival topical anti-inflammatory medications on clinical outcomes, including anterior chamber cell (ACC)/flare and IOP.

Four hundred and eighty-three eyes of 381 patients were treated with dexamethasone intraocular suspension. Seventy-six percent of eyes received ≥1 topical NSAID (mean duration: 23 days); 34% had ≥1 topical steroid (mean: 12 days). Of eyes with a record at each postop day, 73% were given only adjunctive NSAID (no topical steroid) had ACC grade 0 at Day 1, 69% at Day 8, 85% at Day 14, and 93% at Day 30. Of eyes given no adjunctive topical NSAID or steroid, 25% had ACC grade 0 at Day 1; 69% at Day 8; 93% at Day 14 and 95% at Day 30.

Results from the first large-scale retrospective study of dexamethasone intraocular suspension 9% in cataract surgery are similar to those seen in the controlled clinical trials, including early and sustained ACC and flare clearing and mean IOL in normal range throughout the postop period.

Reference
Matossian C, et al. Outcomes with dexamethasone intraocular suspension 9% and concomitant postoperative anti-inflammatory medications. Presented at: AAO 2020 Virtual. [Session: PO051].